Segment, Customer and Geographic Information

9 Months Ended

Sep. 30, 2013

Segment, Customer and Geographic Information

Note 13. Segment, Customer and Geographic Information

The Company continues to operate in only one segment, blood safety. The Company’s chief executive officer is the chief operating decision maker who evaluates performance based on the net revenues and operating loss of the blood safety segment. The Company considers the sale of all of its INTERCEPT Blood System products to be similar in nature and function, and any revenue earned from services is minimal.

The Company’s operations outside of the United States include a wholly-owned subsidiary headquartered in Europe. The Company’s operations in the United States are responsible for the research and development and global commercialization of the INTERCEPT Blood System, as discussed in further detail below, while operations in Europe are responsible for the commercialization efforts of the platelet and plasma systems in Europe, The Commonwealth of Independent States and the Middle East. Product revenues are attributed to each region based on the location of the customer, and in the case of non-product revenues, on the location of the collaboration partner.

The Company had the following significant customers that accounted for more than 10% of the Company’s total product revenue, all of which operate in a country outside of the United States, during the three and nine months ended September 30, 2013, and 2012 (in percentages):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2013			2012			2013			2012
Etablissement Francais du Sang		20	%		22	%		18	%		23	%
Movaco, S.A.		19	%		19	%		16	%		19	%
Bravo Pacific Limited		11	%			*			*			*
Advanced Technology Comp. KSC		10	%			*			*			*
AUM+ LTD			*		13	%			*			*

* Represents an amount less than 10% of product revenue.